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Abstract
OBJECTIVE—To examine the uptake of prenatal tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis (Tdap) immunization among pregnant women in the United States.
METHODS—Using MarketScan data, we conducted a historical cohort study among pregnant 
women with employer-based commercial insurance in the United States who delivered between 
January 1, 2010 and December 31, 2014. We examined temporal trends of uptake, predictors of 
uptake, and timing of Tdap immunization.
RESULTS—Among 1,222,384 eligible pregnancies in 1,147,711 unique women, receipt of 
prenatal Tdap immunization increased from 0.0% of women who delivered in January 2010 to 
9.8% who delivered in October 2012 (the date of the recommendation by the Advisory Committee 
on Immunization Practices for Tdap during every pregnancy) to 44.4% who delivered in 
December 2014. Among women who received Tdap during pregnancy, the majority were 
immunized between 27 weeks and 36 weeks 6 days of gestation, per the ACIP recommendation. In 
multivariable analyses among women who delivered between November 2012 and December 
2014, rates of prenatal Tdap immunization were lower for women under 25 years of age (e.g., 
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20-24 vs. 30-34 years rate ratio [RR], 0.83, 95% confidence interval [CI], 0.85-0.88), with other 
children (e.g., 3 vs. 0 children: RR, 0.86, 95% CI, 0.84-0.88), residing in the South vs. Midwest 
(RR, 0.81, 95% CI, 0.80-0.82), or with emergency department visits in early pregnancy (RR, 0.93, 
95% CI, 0.92-0.95). The proportion of pregnant women who received prenatal Tdap increased 
with increasing gestational age at birth.
CONCLUSION—By the end of 2014, less than half of pregnant women in the US were receiving 
prenatal Tdap immunization. Implementation and dissemination strategies are needed to increase 
Tdap coverage among pregnant women, especially those who are young, have other children, or 
reside in the South.
Graphical abstract
PRÉCIS: Less than half of pregnant women are receiving guideline-recommended tetanus toxoid, 
reduced diphtheria toxoid, and acellular pertussis (Tdap) immunization.
INTRODUCTION
Pertussis incidence has been rising in the United States (US) during the past decade,1 with a 
2014 rate of 169 pertussis cases per 100,000 infants under 6 months of age.1 Disease in 
infants is associated with hospitalization, apnea, pneumonia, and death.1-3 The Centers for 
Disease Control and Prevention (CDC) recommends that infants receive the primary series 
of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) at 2, 4, and 6 
months of age and 2 booster doses later in childhood to protect against pertussis infection.4 
However, maximal protection is not attained until after the third dose at 6 months of age,5,6 
leaving young infants at higher risk of pertussis. Therefore, the Advisory Committee on 
Immunization Practices (ACIP) has made several recent recommendations which were 
adopted by the CDC regarding prenatal or postpartum immunization of mothers with adult 
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) immunization.7-9
Little is known about national adherence to CDC guidelines for Tdap immunization during 
pregnancy. Several studies suggest low uptake, but results are dated and limited to select 
states or regions of the US.10-13 Knowledge about individual, provider, and ecological 
predictors of prenatal Tdap uptake is important to inform public health efforts to improve 
coverage, yet no large studies have identified factors associated with prenatal Tdap receipt. 
Although current evidence is somewhat conflicting,14-17 the timing of Tdap receipt during 
pregnancy may affect the quantity of maternal anti-pertussis antibodies transferred. 
Therefore, we sought to examine temporal trends in uptake, predictors of uptake, and timing 
of Tdap immunization in a large national sample of pregnant women in the US.
MATERIALS AND METHODS
Using data from the MarketScan Commercial Claims and Encounters Databases (Copyright 
© 2014 Truven Health Analytics Inc. All Rights Reserved), we identified a historical cohort 
of women with evidence of a pregnancy outcome at ≥20 weeks gestational age between 
January 1, 2010 and December 31, 2014. The MarketScan databases capture patient-level 
data on inpatient, outpatient, and prescription drug claims from approximately 100 large 
employers and health plans that insure employees and their dependents in all 50 states. In 
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2010, the database included approximately 920,000 pregnant women, corresponding to 
almost 25% of the birth cohort in the US and 50% of the birth cohort in the US with 
commercial insurance.18,19 We required continuous enrollment in a payer plan between the 
estimated date of pregnancy onset and one week postpartum. We defined the delivery date as 
the billing date of an International Classification of Clinical Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) code for outcome of delivery, V27.0–V27.6. The date of 
pregnancy onset was estimated by subtracting the estimated gestational age from the 
delivery date (see Appendix 1, available online at http://links.lww.com/xxx). Multiple 
pregnancies of the same woman during the study period were eligible for inclusion. To 
reduce outcome misclassification from vaccines administered without submitting billing 
claims to insurance, we excluded women ≤18 years of age residing in 13 states with 
universal Vaccines for Children (VFC) programs (Alaska, Hawaii, Maine, Massachusetts, 
New Hampshire, New Mexico, North Carolina, South Dakota, Rhode Island, Vermont, 
Washington, Wisconsin, and Wyoming).20
We evaluated immunization receipt during a time period spanning several changing CDC 
recommendations regarding prenatal or postpartum immunization of women. In 2006, the 
ACIP recommended postpartum immunization of mothers with adult tetanus-diphtheria-
acellular pertussis immunization (Tdap) for those who had not previously received Tdap, as 
part of a strategy known as “cocooning.”9 This strategy had limited success in reducing rates 
of pertussis.21,22 In response, in June 2011, the ACIP voted to recommend that all pregnant 
women receive a single Tdap booster in late pregnancy (>20 weeks gestation) if they had not 
previously received Tdap, in order to convey passive immunity to young infants through 
transplacental IgG antibody transfer.7 Following the recommendation, immunogenicity data 
showed that anti-pertussis antibodies are short-lived and Tdap immunization in a prior 
pregnancy may not protect infants in subsequent pregnancies.17 Therefore, in October 2012, 
ACIP recommended the administration of Tdap in each pregnancy, further defining optimal 
timing for administering Tdap as the time window between 27 and 36 weeks 6 days 
gestation8; the recommendation was approved by the CDC in February 2013.8
We classified Tdap immunization status using inpatient and outpatient ICD-9 procedure 
codes 99.37, 99.39, V06.1 and Current Procedural Terminology (CPT) code 90715, as 
immunization services are coded and billed separately outside the global obstetrician 
packages employed by some insurers.23 We used the October 2012 ACIP recommendation 
to categorize optimal timing of Tdap immunization during pregnancy for all calendar years, 
2010–2014. We categorized Tdap immunization as early prenatal (<27 weeks gestation), 
optimally-timed prenatal (27 weeks to 36 weeks 6 days gestation), late prenatal (≥37 weeks 
gestation), postpartum (≤1 week postpartum), and none (no evidence of prenatal or 
postpartum Tdap immunization). For women who received more than one Tdap 
immunization during pregnancy, categorization was based on the earliest recorded Tdap 
immunization.
Demographic characteristics included maternal age at pregnancy onset; delivery year; 
number of other dependent children; insurance type; network of provider type (in-network, 
out-of-network or mix of networks, no service); geographic region; state; residence within a 
metropolitan statistical area (defined by the US Census Bureau as a geographical region with 
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a high population density at its core and close economic ties throughout the area).24 
Healthcare utilization variables, which served as proxy metrics to identify complicated 
pregnancies, included emergency department visits prior to 20 weeks gestation; and 
overnight hospitalizations prior to 20 weeks gestation. Health insurance type was 
categorized as Preferred Provider Organization (PPO) or Exclusive Provider Organization 
(EPO); Health Maintenance Organization (HMO); Point of Service (POS) or POS with 
capitation; Consumer Directed Health Plan (CDHP); or other (i.e., basic, comprehensive, or 
high-deductible plans). Number of other dependent children was defined as the number of 
other children ≤18 years of age covered by the same insurance plan within the household on 
the delivery date.
Descriptive statistics were generated for individual, provider, and ecological characteristics 
by receipt and timing of Tdap immunization during pregnancy. Analyses were further 
stratified by relevant individual, provider, and ecological characteristics.
To identify individual, provider, and ecological predictors of prenatal Tdap immunization, 
multivariable Cox proportional hazards regression models were used to estimate adjusted 
hazard ratios (HRs), interpreted as rate ratios (RRs), as well as corresponding 95% 
confidence intervals (CIs). Individuals were censored at the earliest of the following; seven 
days after birth, end of continuous enrollment in a health plan, or end of study. The robust 
sandwich estimate of the covariance matrix was specified to allow for clustering at the 
individual-level. Potential predictors of Tdap immunization were determined a priori. 
Mothers with missing data on any potential predictors (6.4%) were excluded from these 
analyses.
To understand the relationship between receipt of prenatal Tdap and gestational age at birth, 
proportions of pregnant women who received prenatal Tdap were calculated by categories of 
preterm, term, and post-term births in the time period after the second recommendation of 
Tdap in pregnancy (November 2012 to December 2014). Corresponding 95% CIs were also 
calculated.
To examine geographic variation, prenatal Tdap coverage was calculated by state in the time 
period after the second ACIP recommendation of Tdap in pregnancy (November 2012 to 
December 2014). A map of the U.S. was created with state values categorized by the quintile 
distribution of the data.
In sensitivity analyses, analyses were stratified by immediate and later periods after the 
October 2012 ACIP recommendation (i.e., 11/2012-12/2013; and 1/2014-12/2014).
SAS software version 9.3 (SAS Institute, Cary, NC) and R Statistical Software version 3.3 
were used to perform all analyses. The institutional review board at the University of North 
Carolina at Chapel Hill approved this research.
RESULTS
Of the 1,222,384 eligible pregnancies among 1,147,711 unique women identified in the 
database (Appendix 2, available online at http://links.lww.com/xxx), prenatal or postpartum 
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Tdap was administered in 241,543 (19.8%) pregnancies. Specifically, 2.4% of pregnancies 
received early prenatal Tdap, 11.0% of pregnancies received optimally-timed prenatal Tdap, 
1.0% of pregnancies received late prenatal Tdap, and 5.4% of pregnancies received 
postpartum Tdap. (Table 1; Appendix 3, available online at http://links.lww.com/xxx) 
Compared to women who received prenatal Tdap, women who did not receive prenatal or 
postpartum Tdap were more likely to have other dependent children, to live in the South, to 
have an in-network provider, or to have had an overnight hospitalization during pregnancy.
The proportion of pregnant women who received prenatal Tdap increased with increasing 
gestational age at birth: 5.9% for extreme preterm (<28 weeks), 11.3% for very preterm (28 
to <32 weeks), 24.5% for moderate to late preterm (32 to <37 weeks), 28.4% for term, and 
34.6% for post-term (Appendix 4, available online at http://links.lww.com/xxx).
The proportion of pregnant women who received prenatal Tdap increased from 0.0% of 
women who delivered in January 2010 to 1.6% of women who delivered in June 2011 (i.e., 
the date of first ACIP recommendation for Tdap during pregnancy) to 9.8% of women who 
delivered in October 2012 (i.e., date of second ACIP recommendation for Tdap during 
pregnancy); thereafter, prenatal Tdap immunization increased sharply to 44.4% of women 
who delivered in December 2014. The timing of Tdap administration changed over time 
(Figure 1). From October 2012 to December 2014, Tdap immunization increased slightly for 
the early (2.2% to 4.2%) and late prenatal period (1.3% to 1.9%), increased sharply for the 
optimally-timed prenatal period (6.3% to 38.3%), and decreased slightly for the postpartum 
period (7.1% to 4.1%).
Temporal trends in prenatal Tdap immunization differed across subgroups (Figure 2). Since 
October 2012, the uptake of Tdap immunization was consistently higher among women of 
older age or with fewer dependent children. Regionally, Tdap immunization was highest in 
the West from mid-2010 to early 2013; and thereafter, highest in the Midwest and lowest in 
the South (Figures 2 and 3).
Among women who delivered between November 2012 and December 2014, variation in 
rates of Tdap immunization were observed across subgroups (Appendix 5, available online 
at http://links.lww.com/xxx). Compared to women 30-34 years of age, rates of Tdap receipt 
were 17% (95% CI, 15-20%) lower among women 14-19 years of age, 13% (95% CI, 
12-15%) lower among women 20-24 years of age, and 5% (95% CI, 4-6%) lower among 
women 25-29 years of age. Tdap rates decreased with increasing number of other dependent 
children. Geographically, Tdap rates were higher among women residing within a 
metropolitan statistical area. Compared to women living in the Midwest, rates of Tdap 
receipt were 19% (95% CI, 18-20%) lower in the South, 18% (95% CI, 17-19%) lower in 
the West, and 16% (95% CI, 14-17%) lower in the Northeast. Rates of Tdap receipt were 
lower among women who had an emergency department visit in early pregnancy. Tdap 
receipt varied by network of provider and health plan type. There were no appreciable 
differences in the predictors of Tdap receipt between immediate and later time periods after 
the October 2012 ACIP recommendation (data not shown).
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We conducted a national study of the uptake of prenatal Tdap immunization among 1.2 
million privately-insured pregnant women in the US from 2010 to 2014. We observed a 
steep increase in prenatal Tdap immunization after the October 2012 ACIP recommendation 
for Tdap immunization during every pregnancy. Yet, national coverage remained below 45% 
by the end of 2014. The majority of prenatal Tdap recipients were immunized between 27 
weeks and 36 weeks 6 days gestation, as encouraged by the ACIP recommendation. Receipt 
of postpartum Tdap was low and increasingly rare, despite the high proportion of 
unimmunized women at delivery, representing lost opportunities for prevention of infant 
pertussis.
For the period before the 2012 ACIP recommendation, our findings of low yet increasing 
coverage are consistent with published reports (i.e., Michigan data on Medicaid-enrollees 
and regional Vaccine Safety Datalink (VSD) data on insured patients seeking care at large 
integrated healthcare systems).11,12 For the period after the 2012 ACIP recommendation, our 
estimates of prenatal coverage are lower than other studies. One possible explanation for this 
discrepancy is that existing studies were conducted in states with exceptionally high 2012 
pertussis incidence, which urged local efforts to increase prenatal coverage. A study in 
Wisconsin, the state with the highest 2012 pertussis incidence, reported an increase in 
prenatal Tdap coverage from January 2013 (13.8%) to March 2014 (51.0%).10,25 A VSD 
study reported 41.7% prenatal Tdap coverage in 2013, which is likely attributable to 
immunization campaigns in response to exceptionally high 2012 pertussis incidence in 
several of these VSD states.13,25 Our most recent national estimate of prenatal Tdap 
coverage (44.4% in December 2014) is slightly lower than national prenatal influenza 
coverage during the 2014/2015 influenza season (50.3%), according to a CDC survey of 
1702 women with a mix of private, public, or no insurance.26
Existing epidemiological studies to identify predictors of Tdap or influenza immunization 
during pregnancy are limited by small sample size, univariate methods, and limited follow-
up after relevant ACIP recommendations.27,28 In multivariable analyses, we identified 
substantial variability in prenatal Tdap immunization across patient subgroups. Specifically, 
rates of prenatal Tdap immunization were lower among women who were younger, had 
more dependent children, experienced an emergency department visit during early 
pregnancy, or accessed an out-of-network provider. Prenatal Tdap immunization also varied 
regionally, which is consistent with national survey data on Tdap immunization among 
women regardless of pregnancy status.29,30 Specifically, prenatal Tdap receipt was highest in 
the Midwest and lowest in the South. Racial disparities in vaccine receipt may partially 
explain the geographic distribution, as Black women are less likely to receive prenatal Tdap 
compared to White women.12 This racial disparity is concerning since Black women are also 
at higher risk of preterm birth, and preterm babies are most vulnerable to pertussis.
We also observed that women who delivered preterm were less likely to receive prenatal 
Tdap. This finding is consistent with previous research11 and provides justification for 
earlier Tdap immunization during pregnancy based on recent evidence that earlier Tdap 
immunization during pregnancy leads to higher neonatal anti-pertussis antibodies and 
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encourages immunization to women who subsequently deliver preterm.15,29 Future research 
is needed to address the safety and effectiveness of prenatal Tdap by gestational age at 
administration.
Further investigation is warranted to understand why pregnant women with PPO or EPO 
insurance plans and those seeing out-of-network providers were less likely to receive 
prenatal Tdap. The Affordable Care Act has mandated removal of co-pays associated with 
vaccines or their administration if vaccines are provided by an in-network provider, 
therefore, women receiving prenatal care from an out-of-network provider may still need to 
share the cost of receiving Tdap. Further, an increasing number of providers may no longer 
be offering vaccines in their offices, due to a reported lack of adequate reimbursement.
Our study had several limitations. First, our study population included only commercially-
insured women. Given lower uptake of prenatal Tdap among women with Medicaid as 
compared to privately-insured women,10 our findings may not be generalizable to women of 
lower socioeconomic status. Second, our ascertainment of Tdap immunization may have 
slightly underestimated vaccine receipt by failing to capture immunizations among women 
who received prenatal Tdap without requesting insurance reimbursement (e.g., self-payment 
or community-based free immunization campaigns). Although immunization administration 
has not been validated in the MarketScan data, our assessment of immunization 
administration is likely to be well-captured given that insurance claims are the basis for 
reimbursement, audited for accuracy, and not subject to recall bias, as in commonly used 
phone surveys or in-person interviews to assess vaccine coverage. Third, information on 
several potentially important factors (e.g., race, ethnicity, and socioeconomic status) were 
not available for analysis since the MarketScan databases do not include these variables. We 
were also unable to reliably identify differences in Tdap receipt by provider type (i.e. 
obstetrician-gynecologist, family physician, midwife) due to difficulties in assessing the 
provider of prenatal care services.
Years after the initial ACIP recommendation for prenatal Tdap immunization, less than half 
of pregnant women in the US are receiving prenatal Tdap immunization. Our findings 
underscore the urgent need for implementation and dissemination strategies to increase Tdap 
coverage among pregnant women. Further research is warranted on the effectiveness of 
interventions to increase demand for Tdap among pregnant women, through strategies such 
as patient reminder and recall systems, clinic-based approaches, and addressing concerns 
about vaccine safety.
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Percent of pregnancies with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis 
(Tdap) immunization, by delivery month and timing of vaccine administration, 2010–2014. 
Grey dotted lines denote the June 2011 Advisory Committee on Immunization Practices 
(ACIP) recommendations for Tdap for unvaccinated pregnant women and October 2012 
ACIP recommendations for Tdap immunization with each pregnancy. Results did not change 
appreciably in the sensitivity analyses that excluded 1,695 (0.1%) women who delivered 
before 27 weeks of gestation.
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Proportion of pregnancies with prenatal tetanus toxoid, reduced diphtheria toxoid, and 
acellular pertussis (Tdap) immunization receipt by delivery month, 2010–2014, by maternal 
age (A), number of other dependent children (B), geographic region of residence (C). Grey 
dotted lines denote the June 2011 Advisory Committee on Immunization Practices (ACIP) 
recommendations for Tdap for unvaccinated pregnant women and October 2012 ACIP 
recommendations for Tdap immunization with each pregnancy.
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Geographic distribution of prenatal tetanus toxoid, reduced diphtheria toxoid, and acellular 
pertussis (Tdap) immunization (%) by state, November 2012–December 2014. Analysis was 
restricted to the time period following the October 2012 Advisory Committee on 
Immunization Practices (ACIP) recommendation.
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Adjusted rate ratio estimates for the associations between prenatal tetanus toxoid, reduced 
diphtheria toxoid, and acellular pertussis (Tdap) vaccine receipt and patient characteristics 
among pregnant women, November 2012–December 2014. A total of 14,829 (6.4%) of 
mothers were excluded from these analyses due to missing data on at least one potential 
predictor (ie, health insurance type, residence within a metropolitan statistical area, and/or 
region of residence). aRR, adjusted rate ratio; CI, confidence interval; HMO, Health 
Maintenance Organization; PPO, Preferred Provider Organization; EPO, Exclusive Provider 
Organization; POS, Point of Service; CDHP, Consumer Directed Health Plan.
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Table 1















  2010 1,690 (1.0) 6,079 (9.3) 179,842 (18.3) 187,611 (15.4)
  2011 5,519 (3.1) 15,841 (24.1) 232,822 (23.7) 254,182 (20.8)
  2012 19,019 (10.8) 19,575 (29.8) 251,585 (25.7) 290,179 (23.7)
  2013 49,901 (28.4) 11,999 (18.3) 164,212 (16.7) 226,112 (18.5)
  2014 99,715 (56.7) 12,205 (18.6) 152,380 (15.5) 264,300 (21.6)
Maternal age at pregnancy
onset (years), median (SD)
30 (5.1) 29.0 (5.3) 30.0 (5.4) 30.0 (5.3)
Number of other dependent
children
  0 76,946 (43.8) 27,862 (42.4) 366,817 (37.4) 471,625 (38.6)
  1 58,780 (33.4) 20,871 (31.8) 331,085 (33.8) 410,736 (33.6)
  2 27,412 (15.6) 11,028 (16.8) 181,680 (18.5) 220,120 (18.0)
  ≥ 3 12,706 (7.2) 5,938 (9.0) 101,259 (10.3) 119,903 (9.8)
Obstetric blood panel prior to 14
weeks gestation
92,068 (52.4) 36,619 (55.7) 481,973 (49.1) 610,660 (50.0)
Overnight hospitalization during
pregnancy
1,030 (0.6) 552 (0.8) 8,304 (0.9) 9,886 (0.8)
Emergency department visit
during pregnancy
22,784 (13.0) 9,433 (14.4) 136,422 (13.9) 168,639 (13.8)
Network of provider type
  In-network 152,483 (86.7) 53,587 (81.6) 759,944 (77.5) 966,014 (79.0)
  Out of network or mix of
networks
22,207 (12.6) 9,567 (14.6) 136,264 (13.9) 168,038 (13.8)
  No service 1,154 (0.7) 2,545 (3.9) 84,633 (8.6) 88,332 (7.2)
Health insurance type
  PPO or EPO 108,659 (61.8) 45,194 (68.8) 645,419 (65.8) 799,272 (65.4)
  HMO 23,963 (13.6) 7,242 (11.0) 121,744 (12.4) 152,949 (12.5)
  POS or POS with capitation 9,802 (5.6) 3,149 (4.8) 53,768 (5.5) 66,719 (5.5)
  CDHP 13,555 (7.7) 3,585 (5.5) 61,842 (6.3) 78,982 (6.5)
  Other 14,554 (8.3) 3,825 (5.8) 56,339 (5.7) 74,718 (6.1)
  Missing 5,311 (3.0) 2,704 (4.1) 41,729 (4.3) 49,744 (4.1)
Region of residence
  Northeast 27,189 (15.5) 8,936 (13.6) 156,092 (15.9) 192,217 (15.7)
  North Central 46,936 (26.7) 14,442 (22.0) 233,437 (23.8) 294,815 (24.1)
  South 48,669 (27.7) 26,029 (39.6) 364,896 (37.2) 439,594 (36.0)
  West 47,493 (27.0) 14,566 (22.2) 201,844 (20.6) 263,903 (21.6)
  Unknown 5,557 (3.2) 1,726 (2.6) 24,572 (2.5) 31,855 (2.6)
Residence within a
metropolitan statistical area



























  No 17,150 (9.8) 7,935 (12.1) 124,623 (12.7) 149,708 (12.3)
  Yes 153,138 (87.1) 56,039 (85.3) 831,692 (84.8) 1,040,869 (85.2)
  Missing 5,556 (3.2) 1,725 (2.6) 24,526 (2.5) 31,807 (2.6)
Abbreviations: CDHP, Consumer Directed Health Plan; EPO, Exclusive Provider Organization; HMO, Health Maintenance Organization; POS, 
Point of Service; PPO, Preferred Provider Organization; SD, standard deviation.
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